Avelumab in Previously Untreated Patients With Epithelial Ovarian Cancer (JAVELIN OVARIAN 100)

Official Title

A Randomized, Open-label, Multicentre, Phase 3 Study To Evaluate The Efficacy And Safety Of Avelumab (msb0010718c) In Combination With And/or Following Chemotherapy In Patients With Previously Untreated Epithelial Ovarian Cancer Javelin Ovarian 100


This is a Phase 3, open-label, international, multi-centre, efficacy, and safety study of avelumab in combination with and/or following platinum-based chemotherapy. Eligible patients must have previously untreated, histologically confirmed Stage II-IV epithelial ovarian (EOC), fallopian tube cancer (FTC), or primary peritoneal cancer (PPC) and be candidates for platinum-based chemotherapy. The primary purpose of the study is to demonstrate if avelumab given as single agent in the maintenance setting following frontline chemotherapy or in combination with carboplatin/paclitaxel is superior to platinum-based chemotherapy alone followed by observation in this population of newly diagnosed ovarian cancer patients.

Trial Description

Primary Outcome:

  • Progression-Free Survival (PFS)
Secondary Outcome:
  • Overall Survival (OS)
  • Maintenance Progression-Free Survival (PFS)
  • Duration of Response (DR)
  • Objective Response Rate - Percentage of Participants With Objective Response
  • EuroQoL5 Dimension (EQ-5D-5L)
  • FOSI-18 [FACT Ovarian Symptom Index-18]
  • ADA [Anti-Drug Antibodies]
  • Presence or absence of predictive candidate biomarkers in tumour tissue
  • Area under the Concentration-Time Curve (AUC)
  • Cmax
  • Volume of Distribution
  • Clearance (CL)
  • Progression Free Survival 2 (PFS2)
  • pathological Complete response (pCR)

View this trial on ClinicalTrials.gov

Interested in this trial?

Print this page and take it to your doctor to discuss your eligibilty and treatment options. Only your doctor can refer you to a clinical trial.


Canadian Cancer Society

These resources are provided in partnership with the Canadian Cancer Society